

BIOMARKER

summit

Includes the three co-located conferences:

8th Oncology Biomarkers
4th Neurological Biomarkers
4th Inflammatory & Immunological Biomarkers

Keynote Speakers

Mark E. Curran
Vice President, Immunology
Systems Pharmacology & Biomarkers
Janssen

Sudhir Srivastava
Chief, Cancer Biomarkers Research Group
Division of Cancer Prevention
National Cancer Institute, NIH

John Wagner
Senior Vice President
Head, Clinical & Translational Sciences
Takeda Pharmaceuticals

MARCH 18-20, 2015 • SAN DIEGO, CA

Platinum Sponsors

abcam[®]
discover more

MYRIAD  RBM


CAPRION

Visit www.gtcbio.com for more information!

Gold Sponsors

Quanterix **Singulex**[®]
high definition diagnostics

Corporate Partner


epiontis

Media Partners

FOCiS[®]
Federation of Clinical
Immunology Societies www.focisnet.org


antibodies[®] -online.com

 **Biocompare**
The Buyer's Guide for Life Scientists

 **Technology
Networks.com**
Scientific Communities

BioCentury[®]

BIOSCREENING.COM
DRUG DISCOVERY PORTAL



**BENTHAM
SCIENCE**

 **BioPharma
DIVE**

The
Journal of
Rheumatology

ABOUT

The [Biomarker Summit 2015](#) will bring together leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization. A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Biomarker Summit 2015 provides a unique opportunity to gain the latest biomarker developments in three major therapeutic areas, formally organized into the following tracks:

[8th Oncology Biomarkers](#)

This meeting provides a forum for experts in industry, academia and government to discuss the latest developments in the oncology biomarker research arena. Topics include circulating tumor cells, cell free DNA, digital pathology and imaging biomarkers.

[4th Neurological Biomarkers](#)

Leading experts will focus on the development of CNS biomarkers for drugs and diagnostics from CSF and blood, as well as imaging approaches.

[4th Inflammatory & Immunological Biomarkers](#)

Delegates will discuss the unmet medical needs in autoimmune diseases, respiratory diseases, kidney disease, lupus, IBD and other inflammatory diseases.

CALL FOR PAPERS

To be considered for a short oral presentation, please submit an abstract by **February 18, 2015**. Selected presentations will be based on quality of abstract and availability. Selected abstracts will be notified via email or telephone 2-3 weeks before the conference. Presentation slots fill up fast so please submit your abstract soon.

Click on the following conferences to submit an abstract:

[8th Oncology Biomarkers](#)

[4th Neurological Biomarkers](#)

[4th Inflammatory & Immunological Biomarkers](#)

SPONSORSHIP OPPORTUNITIES

GTCbio conferences bring together high-level influential leaders with decision-making authority from the pharmaceutical industry, academia, and government. Our approach offers a more intimate and networking-oriented environment geared towards connecting experts within their fields to further collaborate on new and existing research

- Sponsors/exhibitors will receive the delegate list a week before and a week after the conference.
- Meeting exhibit space is shared between all conferences, providing sponsors/exhibitors with access to delegates at all co-located meetings. Exhibitors are located in the same room where all networking functions take place, including coffee breaks, snack stations, breakfast, and reception.
- Your corporate logo will be placed on the cover page of the conference brochures, the USB proceedings given to all conference delegates, and on the presentation screen during all breaks to enhance your company's visibility at the event. Your logo will also be featured on the conference website, with a link to your company's website.

For sponsorship and exhibit opportunities, please contact:

Amber Kempf

Account Executive

amber.kempf@gtcbio.com

SPONSORS

PLATINUM



Singulex is the developer and leading provider of Single Molecule Counting immunoassay technology, enabling groundbreaking discovery and the development of innovative therapies. The proprietary digital SMCTM technology enables scientists to measure proteins across a broad range of concentrations, including endogenous levels, providing unparalleled quantification for biomarker and bioanalytical immunoassay applications. The Singulex Life Science group delivers SMC technology to a global market of academic institutions, leading pharmaceutical and biotechnology laboratories and contract research organizations (CROs) via its Research-Use-Only Erenna® Immunoassay System.

Myriad RBM, Inc. is the world's leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner.



GOLD



Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts.

Abcam is a provider of protein research tools and services, with an unrivaled range of products and expert technical support, enabling scientists to analyze living cells at the molecular level and improving the understanding of health and disease. To find out more, please visit www.abcam.com



Our goal is to make protein analysis simpler, more quantitative and affordable. Our comprehensive portfolio of tools includes Simple Western systems that quantify protein expression and Biologics systems that probe the structure and purity of protein-based therapeutics.



CORPORATE SPONSOR



MEDIA PARTNERS



AGENDA AT A GLANCE

Day 1 -Wednesday March 18, 2015

12:00	Registration
12:55	Welcoming & Opening Remarks
	Plenary Keynote Session
1:00	Transformative Potentials of Biomarkers in Clinical Application: Early Detection, Diagnosis and Prognosis <i>Sudhir Srivastava</i> , Chief, Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, NIH
1:45	<i>Mark E. Curran</i> , Vice President, Immunology, Systems Pharmacology & Biomarkers, Janssen
	Plenary Session: Big Data Analytics for Biomarkers Development
2:30	<i>Colin Hill</i> , Chief Executive Officer, President, Chairman & Co-Founder, GNS Healthcare
2:55	<i>Parag Mallick</i> , Assistant Professor, Canary Center for Cancer Early Detect, Stanford University
3:20	Afternoon Networking and Refreshment Break
3:50	Multimodal and Multiscale Technologies and Analytics for Predictive Biomarker Discovery <i>Chinnappa Kodira</i> , Bioinformatics Strategy Leader, Comp Biology & Biostatistics, GRC, GE Global Research
4:15	Using Big Data Towards Personalized Treatment Selection and Multi-marker Real Time Diagnostics <i>Mohammad M. Afshar</i> , Chief Executive Officer, Ariana Pharma
	Plenary Panel Discussion: Companion Diagnostics Development & Partnering Strategies
4:40	Panelists: <i>Trevor Page</i> , Director, Corporate Business Development, Dako <i>Nicole Jean</i> , Corporate Business Development, Global Product & Portfolio Strategy, AstraZeneca <i>Ian McCaffery</i> , Oncology Biomarker Development, Companion Diagnostics, Genentech <i>Hakan Sakul</i> , Executive Director & Head of Diagnostics, Site Head, Development Operations Worldwide R&D, Clinical Research and Precision Medicine, Pfizer
5:25	Day 1 Concludes

Day 2 -Thursday, March 19, 2015

7:00	Registration & Continental Breakfast		
	Three Concurrent Conferences		
	8th Oncology Biomarkers	4th Neurological Biomarkers	4th Inflammatory & Immunological Biomarkers
8:00	Session I: Liquid Biopsy: Non-Invasive Approaches to Diagnostics	Session I: Imaging Approaches in CNS Drug Discovery & Development	Session I: Biomarkers of Early Progressive Inflammatory & Immunological Diseases
10:05	Morning Networking & Refreshment Break		

AGENDA AT A GLANCE

Day 2 - Thursday, March 19, 2015

	8th Oncology Biomarkers	4th Neurological Biomarkers	4th Inflammatory & Immunological Biomarkers
10:50	Session II: Digital & Molecular Pathology	Session II: CSF & Blood Based Biomarker Approaches	Session II: Biomarkers & Surrogate Endpoints for Clinical Trials in Inflammatory Diseases
12:15	Lunch On Your Own		
1:45	Session III: Emerging Discovery Pipelines	Session III: Developments in Neurological & Neurodegenerative Disorders	Session III: Novel Approaches to Immunological Biomarkers
3:25	Afternoon Networking & Refreshment Break		
3:55	Session IV: Immuno-Oncology Biomarker Discovery	Session IV: Biomarker Development in Neuropsychiatric Disorders	Session IV: Fluid Based Biomarkers Approaches (Synovial, Salivary, Urine)
5:10	Evening Networking Reception & Poster Session		

Day 3 - Friday, March 20, 2015

7:30	Continental Breakfast
	Plenary Keynote Session
8:00	Who Owns Biomarker Qualifications and Surrogate Endpoints? <i>John Wagner</i> , Senior Vice President, Head, Clinical & Translational Sciences, Takeda Pharmaceuticals
	Plenary Session: Novel Technologies in Biomarker Development
8:45	Activity-based Probes: Novel Tools in Biomarker Development <i>Amos Baruch</i> , Scientist, Development Sciences, Genentech
9:10	Novel Biomarkers Through Precise Definition of Immune Repertoires <i>Guy Cavet</i> , Chief Technology Officer, Atreca
9:35	MRM-based Multiplexed Quantification of Proteins and Phospho-signaling in Tissues and Cell Lines <i>Amanda Paulovich</i> , Associate Member, Clinical Research Division; Early Detection Initiative, Fred Hutchinson Cancer Research
10:00	Morning Networking Break
10:30	<i>Hongjie Dai</i> , Professor, Stanford University
10:55	Frequent Regulatory Variants in Drug Target Genes: Potential for Predictive Biomarker Panels <i>Wolfgang Sadee</i> , Felts Mercer Professor, Medicine & Pharmacology, Ohio State University
	Plenary Session: Overcoming Challenges of Clinical Validation & Translation
11:20	Can We Use Biomarkers to Successfully Make Decisions Prior to Large Outcomes Trials in Cardiovascular Drug Development? <i>David Kallend</i> , Vice President & Global Medical Director, The Medicines Company
11:45	Lunch Provided by GTCbio

All times are approximate and subject to changes without notice

AGENDA AT A GLANCE

Day 3 - Friday, March 20, 2015

Plenary Session: Overcoming Challenges of Clinical Validation & Translation (cont.)

12:45 *Ian McCaffery*, Oncology Biomarker Development, Companion Diagnostics, **Genentech**

1:10 **Consideration for the Use of Comprehensive Genomic Profiling in Oncology Clinical Care and Clinical Trials**
Roman Yelensky, Senior Director, Biomarker & Companion Diagnostic Development, **Foundation Medicine**

Plenary Panel Discussion: Non-Profits Perspectives on Biomarkers

1:35 **Panelists:**

Douglas Macdonald, Director, Drug Discovery & Development, **CHDI Foundation**

Lucie Bruijn, Chief Scientist, **The ALS Association**

Tim Turnham, Executive Director, **Melanoma Research Foundation**

Plenary Panel Discussion: Regulatory & Reimbursement Trends in Biomarker Development

2:20 **Panelists:**

Jennifer Madsen, Senior Director, Economic & Regulatory Affairs, **College of American Pathologists**

TBD

3:05 *Conferences Conclude*

PLENARY KEYNOTE SPEAKERS



Sudhir Srivastava
Chief, Cancer Biomarkers Research Group
Division of Cancer Prevention
National Cancer Institute, NIH



Mark E. Curran
Vice President, Immunology
Systems Pharmacology & Biomarkers
Janssen



John Wagner
Senior Vice President
Head, Clinical & Translational Sciences
Takeda Pharmaceuticals




Hakan Sakul
Executive Director & Head of Diagnostics
Site Head, Development Operations Worldwide R&D,
Clinical Research and Precision Medicine
Pfizer

PLENARY SPEAKERS



Using Big Data Towards Personalized Treatment Selection and Multi-marker Real Time Diagnostics

Mohammad M. Afshar
Ariana Pharma



Plenary Panel Discussion: Companion Diagnostics Development & Partnering Strategies

Nicole Jean
AstraZeneca



Activity-based Probes: Novel Tools in Biomarker Development

Amos Baruch
Genentech



Can We Use Biomarkers to Successfully Make Decisions Prior to Large Outcomes Trials in Cardiovascular Drug Development?

David Kallend
The Medicine Company



Plenary Panel Discussion: Non-profits Perspectives on Biomarkers

Lucie Bruijn
The ALS Association



Multimodal and Multiscale Technologies And Analytics for Predictive Biomarker Discovery

Chinnappa Kodira
GE Global Research



Novel Biomarkers Through Precise Definition of Immune Repertoires

Guy Cavet
Atreca



Plenary Panel Discussion: Non-Profits Perspectives on Biomarkers

Douglas Macdonald
CHDI Foundation



Hongjie Dai
Stanford University



Parag Mallick
Stanford University



Colin Hill
GNS Healthcare



Plenary Panel Discussion: Companion Diagnostics Development & Partnering Strategies


Ian McCaffery
Genentech

PLENARY SPEAKERS



Plenary Panel Discussion: Regulatory & Reimbursement Trends in Biomarker Development

Jennifer Madsen
College of American Pathologists



Frequent Regulatory Variants in Drug Target Genes: Potential for Predictive Biomarker Panels

Wolfgang Sadee
Ohio State University



Plenary Panel Discussion: Companion Diagnostics Development & Partnering Strategies

Trevor Page
Dako




Plenary Panel Discussion: Non-Profits Perspectives on Biomarkers

Tim Turnham
Melanoma Research Foundation



MRM-based Multiplexed Quantification of Proteins and Phospho-signaling in Tissues and Cell Lines

Amanda Paulovich
Fred Hutchinson Cancer Research



Considerations for the Use of Comprehensive Genomic Profiling in Oncology Clinical Care and Clinical Trials

Roman Yelensky
Foundation Medicine

8TH ONCOLOGY BIOMARKERS - DISTINGUISHED SPEAKERS



Developing Blood Based Biomarkers for Early Detection and Screening in Cancer

Wendy Alderton
Abcodia



Fiona Ginty
GE Healthcare



Approaches to Jointly Validate Biomarkers and Identify Targets for Cancer

Raj Batra
UCLA Geffen School of Medicine, VAGLAHS



Charles Glaus
Amgen



Assessing Pre-analytical Variables in the Context of Oncology Proteomic Biomarker Discovery in Plasma, FFPE and Frozen Tissue

Daniel Chelsky
Caprion Proteomics



Jack Gorskopf
Hologic

8TH ONCOLOGY BIOMARKERS - DISTINGUISHED SPEAKERS



Stephen Johnston
**Biodesign Institute,
Arizona State University**



Developing CTC Assays to Support Early Clinical Trials of Targeted Therapies

Steven Pirie-Shepherd
Pfizer



Ann Kapoun
OncoMed Pharmaceuticals



Christine Skibola
University of Alabama at Birmingham



Tadd Lazarus
Qiagen



Automated Genomic Interpretation of Sub-chromosomal Fetal Copy Number Variation by Sequencing Circulating Cell-free DNA from Maternal Plasma
Ali Torkamani
The Scripps Translational Science Institute, The Scripps Research Institute



Clinical Proteomics Pipeline for Biomarker Discovery & Validation

Pierluigi Mauri
Proteomics & Metabolomics Laboratory - CNR; Institute for Biomedical Technologies (ITB-CNR)



Fengrong Zuo
MedImmune

4TH NEUROLOGICAL BIOMARKERS - DISTINGUISHED SPEAKERS



Denes Agoston
School of Medicine, USU



Robert Rissman
University of California San Diego



Use of MDD Score for the Identification of Comorbid Major Depressive Disorder (MDD) in Patients with Chronic Pain

John Bilello
Ridge Diagnostics



Cristina Sampaio
CHDI Foundation



Biomarker Development in Mood Disorders

Maura Furey
Janssen Pharmaceuticals



Disease Heterogeneity and the Development of Stratification Biomarkers for New Asthma Therapeutics

Mary Savage
Merck



Patrizia Fanara
Kinemed



Holly Soares
Bristol-Myers Squibb



Development and Application of PET Imaging Probes for Neurodegenerative Diseases

Hartmuth Kolb
Janssen R&D



Margaret Sutherland
National Institute of Neurological Disorders & Stroke (NINDS), NIH



Translational Biomarkers for Alzheimer's Disease (AD) Drug Development and Plasma AD Biomarker Research

Yoshiya Oda
Eisai



Xuemei Zhao
Merck



Gulín Oz
University of Minnesota

4TH INFLAMMATORY & IMMUNOLOGICAL BIOMARKERS - DISTINGUISHED SPEAKERS



Alex Abbas
Genentech



Mass Spectrometric Immunoassays for Immunological Biomarkers

Dobrin Nedelkov
Arizona State University



Novel Approaches to Identification of Predictors of Response in Heterogeneous Immunologic Diseases

Carrie Brodmerkel
Janssen R&D



Satish Ramachandra
University of California San Diego



Lucie Bruijn
The ALS Association



Attila Seyhan
Florida Hospital, Massachusetts Institute of Technology



Understanding Low-Level C-Peptide Secretion as a Biomarker for Risk of Complications in Type 1 Diabetes

Denise Faustman
Massachusetts General Hospital, Harvard Medical School



Disease Heterogeneity and the Development of Stratification Biomarkers for New Asthma Therapeutics

Dirk Smith
Amgen



The Next Generation of Translational Research

Brian Idoni
Sanguine BioSciences, Inc.



Ziad Taib
AstraZeneca



Selecting Biomarkers to Accelerate Drug Development in Nephrology

Mahmoud Loghman-Adham
Baxter Healthcare



Biomarker Discovery and Development for Acute & Chronic Inflammatory Conditions in Heart, Lung & Kidney Diseases

Scott Tebbutt
The Centre of Excellence for Prevention of Organ Failure

CONFERENCE DETAILS

REGISTRATION

Early Registration Discount:

20% until January 18, 2015

10% until February 18, 2015

Register for 2 the 3rd goes FREE with coupon code: **RCDVB**To register online, visit: <https://www.gtcbio.com/register/biomarkers-summit>

	Commercial	Academic / Govt	Student
Summit	2095.00	1095.00	945.00
Individual Conference	1895.00	895.00	745.00

QUICK REGISTRATION - FAX TO 626-466-4433

First Name: _____ Last Name: _____

Title: _____ Company: _____

Discount Coupon Code: _____

Card #: _____ Exp. Date: _____ CSV #: _____

Cardholder Name: _____

Signature: _____

Billing Address: _____

City: _____ State: _____ Zip: _____

VENUE

The Westin San Diego

400 West Broadway

San Diego, CA 92101

619-239-4500

Discounted Group Rate: \$209.00 per night**Discount Deadline: February 24, 2015**

Mention GTC to receive the group rate.

Online Reservations:

<https://www.starwoodmeeting.com/Book/Biomarker>

PROCEEDINGS

If you are unable to attend the conference you can purchase the proceedings by downloading the order form [here](#). Fill out the order form and fax it to 1 (626) 433-4433 or email it to proceedings@gtcbio.com.